Business

Stocks making the biggest moves midday: Procter & Gamble, Capital One, GrubHub & more

Traders work on the floor of the New York Stock Exchange (NYSE) on November 18, 2014 in New York City.

Spencer Platt | Getty Images News | Getty Images

Check out the companies making headlines midday:

Procter & Gamble — Shares of Procter & Gamble jumped 4.4% to a record high on better-than-expected quarterly numbers and upbeat forecast for the year. P&G reported adjusted earnings per share of $1.10 on revenue of $17.09 billion, topping Refinitiv estimates of $1.05 earnings per share and revenue of $16.86 billion. The results do not include an $8 billion write-down from Procter’s Gillette brand. Procter also sees adjusted earnings per share increasing between 4% and 9% in the fiscal 2020.

Capital One Financial — The bank’s stock fell more than 7% after Capital One disclosed a data breach that compromised data of more than 100 million clients in the U.S. Capital One said the breach could cost it between $100 million and $150 million. RBC Capital Markets analyst Jon Arfstrom said it could also result in “longer term reputational damage.”

Merck — Merck ticked up 1% after the pharmaceutical company’s second-quarter results surpassed Wall Street’s estimates. The company reported earnings per share of $1.30 on revenue of $11.76 billion. Analysts surveyed by Refintiv had expected earnings per share of $1.16 on revenue of $10.96 billion. Surging sales of Keytruda immunotherapy drove growth for Merck. Sales of the company’s Gardasil vaccine and vaccines to children, like the MMR vaccine for measles, were also up over the quarter.

Martin Marietta Materials — Martin Marietta jumped 8% after the materials company raised its earnings and revenue guidance for 2019. The company expects earnings to range between $1.2 billion and $1.315 billion and revenue to range between $4.26 billion and $4.43 billion. The company previously expected to make between $1.17 billion and $1.28 billion in earnings and between $4.23 billion and $4.38 billion in revenue.

Pfizer — Shares of Pfizer tanked more than 6% after Morgan Stanley downgraded the stock to equal-weight from overweight and slashed it price target to $40 per share from $48 per share. The firm said although the mega-pharmaceutical deal between Pfizer and Mylan is a “strategically sound deal,” the move “revealed earnings power that is much weaker than we realized. “

Stitch Fix — Shares of the online clothing company traded 4.5% lower after Amazon launched Personal Shopper. Amazon’s new services uses human stylists and algorithms to pick out clothes for users.

Wabtec — Shares of the passenger rail transport company rallied 8.3% on better-than-expected quarterly results. The company reported adjusted earnings per share of $1.06 on revenue of $2.24 billion. Analysts polled by Refinitiv expected a profit of 98 cents a share on sales of $2.23 billion.

Under Armour — Under Armour fell more than 11% on Tuesday after the apparel company said it expects North American sales to be down for the year after previously guiding them as “relatively flat.”

Gartner — Shares of the tech company plunged more than 19% after Gartner cut its 2019 earnings forecast. Gartner expects earnings to range between $3.39 per share and $3.64. The company had previously forecast earnings to range between $3.82 per share and $4.19.

GrubHub — Shares of GrubHub plunged more than 9% after the food delivery company whiffed on consensus earnings expectations for its fiscal second quarter as rising costs outpaced sales growth. GrubHub earned 27 cents per share, excluding certain items, while analysts expected 30 cents per share, according to Refinitiv.

—CNBC’s Mallika Mitra, Jesse Pound and Maggie Fitzgerald contributed to this report.

Articles You May Like

6 New Retirement Rules And Tax Changes Everyone Should Know
44% of workers are ‘cautiously optimistic’ about meeting retirement goals, CNBC poll finds. Here are key planning steps at every age
China’s ultra-rich population sees ‘dramatic’ growth in last 10 years, outpacing the U.S., report shows
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
LVMH and Formula One announce 10-year partnership

Leave a Reply

Your email address will not be published. Required fields are marked *